1. Home
  2. ASMB vs GLRE Comparison

ASMB vs GLRE Comparison

Compare ASMB & GLRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Assembly Biosciences Inc.

ASMB

Assembly Biosciences Inc.

N/A

Current Price

$28.24

Market Cap

440.0M

Sector

Health Care

ML Signal

N/A

Logo Greenlight Capital Re Ltd.

GLRE

Greenlight Capital Re Ltd.

N/A

Current Price

$14.95

Market Cap

481.5M

Sector

Finance

ML Signal

N/A

Company Overview

Basic Information
Metric
ASMB
GLRE
Founded
2005
2004
Country
United States
Cayman Islands
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Property-Casualty Insurers
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
440.0M
481.5M
IPO Year
2010
2007

Fundamental Metrics

Financial Performance
Metric
ASMB
GLRE
Price
$28.24
$14.95
Analyst Decision
Strong Buy
Analyst Count
6
0
Target Price
$43.40
N/A
AVG Volume (30 Days)
92.6K
81.3K
Earning Date
01-01-0001
06-15-2026
Dividend Yield
N/A
N/A
EPS Growth
50.00
75.00
EPS
N/A
2.17
Revenue
N/A
$729,777,000.00
Revenue This Year
$33.33
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
$6.86
Revenue Growth
N/A
4.85
52 Week Low
$7.76
$11.57
52 Week High
$39.71
$15.12

Technical Indicators

Market Signals
Indicator
ASMB
GLRE
Relative Strength Index (RSI) 48.18 66.04
Support Level $26.50 $12.49
Resistance Level $30.66 $15.06
Average True Range (ATR) 1.46 0.32
MACD 0.04 0.08
Stochastic Oscillator 36.74 88.28

Price Performance

Historical Comparison
ASMB
GLRE

About ASMB Assembly Biosciences Inc.

Assembly Biosciences Inc is a clinical-stage biotechnology company. It is advancing two platform programs, a novel class of oral therapeutics for the treatment of hepatitis B virus (HBV) infection and novel class of oral synthetic live biotherapeutics, which are designed to restore health to a dysbiotic microbiome. The company's HBV-cure program is aimed at increasing the current low cure rate for patients with HBV and is pursuing multiple drug candidates that inhibit multiple steps of the HBV lifecycle. Assembly has discovered several novel core protein Allosteric Modulators, which are small molecules that directly target and allosterically modulate the HBV core protein. The majority of the revenue is generated from the HBV cure program.

About GLRE Greenlight Capital Re Ltd.

Greenlight Capital Re Ltd offers property and casualty reinsurance. Its customers are property and casualty insurers, and Greenlight takes on some of their risk in exchange for insurance premiums. It operates through one operating segment: property and casualty reinsurance. It generates revenue through premiums from reinsurance on property and casualty business assumed and income from investments.

Share on Social Networks: